Literature DB >> 22182452

WITHDRAWN: Cardamonin Inhibits Osteoclastogenesis Induced by Tumor Cells Through Interruption of the Signaling Pathway Activated by Receptor Activator of NF-κB Ligand.

Vivek R Yadav1, Sahdeo Prasad, Simone Reuter, Bokyung Sung, Norio Yamamoto, Akira Murakami, Bharat B Aggarwal.   

Abstract

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
Copyright © 2012. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Year:  2011        PMID： 22182452      PMCID： PMC3769506          DOI： 10.1016/j.canlet.2011.12.011

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  42 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

2.  Biological characterization of interleukin-1-like cytokine produced by cultured bone cells from newborn mouse calvaria.

Authors:  S Hanazawa; S Amano; K Nakada; Y Ohmori; T Miyoshi; K Hirose; S Kitano
Journal:  Calcif Tissue Int       Date:  1987-07       Impact factor: 4.333

3.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.

Authors:  Hiroshi Takayanagi; Sunhwa Kim; Takako Koga; Hiroshi Nishina; Masashi Isshiki; Hiroki Yoshida; Akio Saiura; Miho Isobe; Taeko Yokochi; Jun-ichiro Inoue; Erwin F Wagner; Tak W Mak; Tatsuhiko Kodama; Tadatsugu Taniguchi
Journal:  Dev Cell       Date:  2002-12       Impact factor: 12.270

Review 4.  Receptor activator of nuclear factor kappa B ligand (RANKL): another link between breast and bone.

Authors:  T J Martin; M T Gillespie
Journal:  Trends Endocrinol Metab       Date:  2001 Jan-Feb       Impact factor: 12.015

5.  Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors.

Authors:  S Wei; S L Teitelbaum; M W Wang; F P Ross
Journal:  Endocrinology       Date:  2001-03       Impact factor: 4.736

6.  NF-kappaB-inducing kinase and IkappaB kinase participate in human T-cell leukemia virus I Tax-mediated NF-kappaB activation.

Authors:  M Uhlik; L Good; G Xiao; E W Harhaj; E Zandi; M Karin; S C Sun
Journal:  J Biol Chem       Date:  1998-08-14       Impact factor: 5.157

7.  Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation.

Authors:  F P L Lai; M Cole-Sinclair; W-J Cheng; J M W Quinn; M T Gillespie; J W Sentry; H-G Schneider
Journal:  Br J Haematol       Date:  2004-07       Impact factor: 6.998

8.  American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.

Authors:  Robert A Kyle; Gary C Yee; Mark R Somerfield; Patrick J Flynn; Susan Halabi; Sundar Jagannath; Robert Z Orlowski; David G Roodman; Patricia Twilde; Kenneth Anderson
Journal:  J Clin Oncol       Date:  2007-05-21       Impact factor: 44.544

9.  Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.

Authors:  Michel Jourdan; Jérôme Moreaux; John De Vos; Dirk Hose; Karène Mahtouk; Matthieu Abouladze; Nicolas Robert; Marion Baudard; Thierry Rème; Angela Romanelli; Hartmut Goldschmidt; Jean-François Rossi; Michel Dreano; Bernard Klein
Journal:  Br J Haematol       Date:  2007-06-03       Impact factor: 6.998

10.  I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss.

Authors:  Maria Grazia Ruocco; Shin Maeda; Jin Mo Park; Toby Lawrence; Li-Chung Hsu; Yixue Cao; Georg Schett; Erwin F Wagner; Michael Karin
Journal:  J Exp Med       Date:  2005-05-16       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.